Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions

Abstract

Cyclin-dependent kinases (CDKs) are important regulatory enzymes in the normal physiological processes that drive cell-cycle transitions and regulate transcription. Virtually all cancers harbour genomic alterations that lead to the constitutive activation of CDKs, resulting in the proliferation of cancer cells. CDK inhibitors (CKIs) are currently in clinical use for the treatment of breast cancer, combined with endocrine therapy. In this review, we describe the potential of CKIs for the treatment of cancer with specific focus on glioblastoma (GBM), the most common and aggressive primary brain tumour in adults. Despite intense effort to combat GBM with surgery, radiation and temozolomide chemotherapy, the median survival for patients is 15 months and the majority of patients experience disease recurrence within 6-8 months of treatment onset. Novel therapeutic approaches are urgently needed for both newly diagnosed and recurrent GBM patients. In this review, we summarise the current preclinical and clinical findings emphasising that CKIs could represent an exciting novel approach for GBM treatment.

Keywords

Cyclin-dependent kinases / cyclin-dependent kinase inhibitors / gliomas / glioblastoma / clinical trials / resistance

References

[1] Graña X.Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)..Oncogene1995;11:211-9

[2] Malumbres M.To cycle or not to cycle: a critical decision in cancer..Nat Rev Cancer2001;1:222-31

[3] Malumbres M.Cell cycle, CDKs and cancer: a changing paradigm..Nat Rev Cancer2009;9:153-66

[4] Hanahan D.Hallmarks of cancer: the next generation..Cell2011;144:646-74

[5] Finn RS,Conklin D,Cohen DJ.PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro..Breast Cancer Res2009;11:R77 PMCID:PMC2790859

[6] Hortobagyi GN,Burris HA,Sonke GS.Ribociclib as first-line therapy for HR-positive, advanced breast cancer..N Engl J Med2016;375:1738-48

[7] Goetz MP,Campone M,Paluch-Shimon S.MONARCH 3: abemaciclib as initial therapy for advanced breast cancer..J Clin Oncol2017;35:3638-46

[8] Crespo I,Gonzalez-Tablas M,Otero A.Molecular and genomic alterations in glioblastoma multiforme..Am J Pathol2015;185:1820-33

[9] Hayashi T,Ohba S.The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells..J Neurooncol2013;115:169-78

[10] Bose P,Grant S.Cyclin-dependent kinase inhibitor therapy for hematologic malignancies..Expert Opin Investig Drugs2013;22:723-38 PMCID:PMC4039040

[11] Taylor JW,Phillips JJ,Molinaro AM.Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma..J Neurooncol2018;140:477-83 PMCID:PMC6239922

[12] Kleihues P,Scheithauer BW.The new WHO classification of brain tumours..Brain Pathol1993;3:255-68

[13] Louis DN,Wiestler OD,Burger PC.The 2007 WHO classification of tumours of the central nervous system..Acta Neuropathol2007;114:97-109 PMCID:PMC1929165

[14] Karcher S,Ahmadi R,Vasvari G.Different angiogenic phenotypes in primary and secondary glioblastomas..Int J Cancer2006;118:2182-9

[15] Kleihues P.Primary and secondary glioblastomas: from concept to clinical diagnosis..Neuro Oncol1999;1:44-51 PMCID:PMC1919466

[16] Li R,Yan W,Bao Z.Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution..Oncotarget2015;6:7318-24 PMCID:PMC4466687

[17] Korshunov A,Golanov A.Genetically distinct and clinically relevant subtypes of glioblastoma defined by array-based comparative genomic hybridization (array-CGH)..Acta Neuropathol2006;111:465-74

[18] Morokoff A,Gogos A.Molecular subtypes, stem cells and heterogeneity: implications for personalised therapy in glioma..J Clin Neurosci2015;22:1219-26

[19] Ohgaki H.The definition of primary and secondary glioblastoma..Clin Cancer Res2013;19:764-72

[20] Verhaak RG,Purdom E,Qi Y.Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1..Cancer Cell2010;17:98-110 PMCID:PMC2818769

[21] Cooper LA,Long Q,Cholleti SR.The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas..PLoS One2010;5:e12548 PMCID:PMC2933229

[22] Ducray F,de Reynies A,Thillet J.Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile..Mol Cancer2008;7:41 PMCID:PMC2415112

[23] Johnson BE,Hong C,Aihara K.Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma..Science2014;343:189-93 PMCID:PMC3998672

[24] Phillips HS,Chen R,Soriano RH.Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis..Cancer Cell2006;9:157-73

[25] Network CGAR.Comprehensive genomic characterization defines human glioblastoma genes and core pathways..Nature2008;455:1061-8 PMCID:PMC2671642

[26] Wang Q,Hu X,Squatrito M.Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment..Cancer Cell2017;32:42-56.e6 PMCID:PMC5599156

[27] Hegi ME,Gorlia T,de Tribolet N.MGMT gene silencing and benefit from temozolomide in glioblastoma..N Engl J Med2005;352:997-1003

[28] Stupp R,van den Bent MJ,Fisher B.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma..N Engl J Med2005;352:987-96

[29] Quiros S,Kaina B.Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles..Cell Cycle2010;9:168-78

[30] Murphy AC,Schmid J,Rehm M.Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach..Cell Death Dis2013;4:e629 PMCID:PMC3674364

[31] Mirimanoff RO,Mason W,Kortmann RD.Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial..J Clin Oncol2006;24:2563-9

[32] Cai X.Glioblastoma: new therapeutic strategies to address cellular and genomic complexity..Oncotarget2018;9:9540-54 PMCID:PMC5823664

[33] Upadhyay RK.Drug delivery systems, CNS protection, and the blood brain barrier..Biomed Res Int2014;2014:869269 PMCID:PMC4127280

[34] Fulda S.Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy..Oncogene2006;25:4798-811

[35] Donson AM,Handler MH,Foreman NK.MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma..Pediatr Blood Cancer2007;48:403-7

[36] Ruano Y,Camacho FI,Fiano C.Identification of survival-related genes of the phosphatidylinositol 3’-kinase signaling pathway in glioblastoma multiforme..Cancer2008;112:1575-84

[37] Strik H,Streffer J,Wickboldt J.BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy..J Neurol Neurosurg Psychiatry1999;67:763-8 PMCID:PMC1736652

[38] Fulda S.Molecular pathways: targeting inhibitor of apoptosis proteins in cancer--from molecular mechanism to therapeutic application..Clin Cancer Res2014;20:289-95

[39] Hsieh P.DNA mismatch repair: molecular mechanism, cancer, and ageing..Mech Ageing Dev2008;129:391-407 PMCID:PMC2574955

[40] Russell P.cdc25+ functions as an inducer in the mitotic control of fission yeast..Cell1986;45:145-53

[41] Draetta G,Potashkin J.Identification of p34 and p13, human homologs of the cell cycle regulators of fission yeast encoded by cdc2+ and suc1+..Cell1987;50:319-25

[42] Sherr CJ.Cancer cell cycles..Science1996;274:1672-7

[43] Nurse P,Hartwell L.Understanding the cell cycle..Nat Med1998;4:1103-6

[44] Chen YJ,Wang Z,Costa RH.A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclin-CDK1..J Biol Chem2009;284:30695-707 PMCID:PMC2781623

[45] Marais A,Child ES,Mann DJ.Cell cycle-dependent regulation of the forkhead transcription factor FOXK2 by CDK.cyclin complexes..J Biol Chem2010;285:35728-39 PMCID:PMC2975197

[46] Tomashevski A,Grammas P,Kruman II.Cyclin-C-dependent cell-cycle entry is required for activation of non-homologous end joining DNA repair in postmitotic neurons..Cell Death Differ2010;17:1189-98 PMCID:PMC2885568

[47] Aggarwal P,Kim JK,Gurung B.Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase..Cancer Cell2010;18:329-40 PMCID:PMC2957477

[48] Dickinson LA,Ehley J.Cyclin L is an RS domain protein involved in pre-mRNA splicing..J Biol Chem2002;277:25465-73

[49] Loyer P,Grenet JA,Corlu A.Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection..J Biol Chem2008;283:7721-32

[50] Lam PY,Ng HK,Roussel MF.Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme..Br J Neurosurg2000;14:28-32

[51] Ye X,Harper JW.A premature-termination mutation in the Mus musculus cyclin-dependent kinase 3 gene..Proc Natl Acad Sci U S A2001;98:1682-6 PMCID:PMC29317

[52] Patrick GN,Nikolic M,Dikkes P.Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration..Nature1999;402:615-22

[53] Shupp A,Pestell RG.Biological functions of CDK5 and potential CDK5 targeted clinical treatments..Oncotarget2017;8:17373-82 PMCID:PMC5370047

[54] Hagmann H,Pippin JW,Benzing T.Cyclin I and p35 determine the subcellular distribution of Cdk5..Am J Physiol Cell Physiol2015;308:C339-47

[55] Harper JW.The role of Cdk7 in CAK function, a retro-retrospective..Genes Dev1998;12:285-9

[56] Serizawa H,Conaway JW,Weinberg RA.Association of Cdk-activating kinase subunits with transcription factor TFIIH..Nature1995;374:280-2

[57] Shiekhattar R,Fisher RP,Dynlacht B.Cdk-activating kinase complex is a component of human transcription factor TFIIH..Nature1995;374:283-7

[58] Hengartner CJ,Liao SM,Koh SS.Temporal regulation of RNA polymerase II by Srb10 and Kin28 cyclin-dependent kinases..Mol Cell1998;2:43-53

[59] Rickert P,Lees E.Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases..Oncogene1999;18:1093

[60] Morgan DO.Cyclin-dependent kinases: engines, clocks, and microprocessors..Annu Rev Cell Dev Biol1997;13:261-91

[61] Kasten M.Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity..Oncogene2001;20:1832-8

[62] Yu DS,Hsu EL,Ye F.Cyclin-dependent kinase 9-cyclin K functions in the replication stress response..EMBO Rep2010;11:876-82 PMCID:PMC2966956

[63] Bagella L,Simone C.Identification of murine cdk10: association with Ets2 transcription factor and effects on the cell cycle..J Cell Biochem2006;99:978-85

[64] Boyer MJ.The CDK inhibitors: potential targets for therapeutic stem cell manipulations?.Gene Therapy2008;15:117-25

[65] Roussel MF.The INK4 family of cell cycle inhibitors in cancer..Oncogene1999;18:5311-7

[66] Marques-Torrejon MA,Banito A,Lopez-Contreras AJ.Cyclin-dependent kinase inhibitor p21 controls adult neural stem cell expansion by regulating Sox2 gene expression..Cell Stem Cell2013;12:88-100 PMCID:PMC3714747

[67] Pippa R,Gundem G,Dominguez A.p27Kip1 represses transcription by direct interaction with p130/E2F4 at the promoters of target genes..Oncogene2012;31:4207-20

[68] Li H,Villasante A,Lynch CJ.p27(Kip1) directly represses Sox2 during embryonic stem cell differentiation..Cell Stem Cell2012;11:845-52 PMCID:PMC3549496

[69] Akiyama T,Sumida S,Toyoshima K.Phosphorylation of the retinoblastoma protein by cdk2..Proc Natl Acad Sci U S A1992;89:7900-4 PMCID:PMC49822

[70] Chung J,Baek WK,Kwon TK.Expression of RB C pocket fragments in HSF induces delayed cell cycle progression and sensitizes to apoptosis upon cellular stresses..Cell Prolif2002;35:247-56

[71] Wu CL,Ngwu C,Lees JA.In vivo association of E2F and DP family proteins..Mol Cell Biol1995;15:2536-46 PMCID:PMC230484

[72] Munger K.Human papillomavirus immortalization and transformation functions..Virus Res2002;89:213-28

[73] Brugarolas J,Boyd SD,Jacks T.Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation..Proc Natl Acad Sci U S A1999;96:1002-7 PMCID:PMC15340

[74] Zhu X,Bohmer RM,Assoian RK.Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein..J Cell Biol1996;133:391-403 PMCID:PMC2120799

[75] Lim S.Cdks, cyclins and CKIs: roles beyond cell cycle regulation..Development2013;140:3079-93

[76] Bregman DB,Kidd VJ.Cell cycle regulation and RNA polymerase II..Front Biosci2000;5:D244-57

[77] Nemet J,Rubelj I.The two faces of Cdk8, a positive/negative regulator of transcription..Biochimie2014;97:22-7

[78] Garriga J.Cellular control of gene expression by T-type cyclin/CDK9 complexes..Gene2004;337:15-23

[79] Asghar U,Turner NC.The history and future of targeting cyclin-dependent kinases in cancer therapy..Nat Rev Drug Discov2015;14:130-46 PMCID:PMC4480421

[80] Schwartz GK,Dickson MA,Shaik MN.Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)..Br J Cancer2011;104:1862-8 PMCID:PMC3111206

[81] Murphy C.The role of CDK4/6 inhibition in breast cancer..Oncologist2015;20:483-490 PMCID:PMC4425391

[82] Finn R,Rugo H,Im SA.PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC)..J Clin Oncol2016;34:507

[83] Cristofanilli M,Bondarenko I,Im SA.Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial..Lancet Oncol2016;17:425-39

[84] Slamon DJ,Chia S,De Laurentiis M.Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3..J Clin Oncol2018;36:2465-72

[85] Tripathy D,Colleoni M,Bardia A.Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial..Lancet Oncol2018;19:904-15

[86] Gelbert LM,Lin X,Del Prado M.Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine..Invest New Drugs2014;32:825-37 PMCID:PMC4169866

[87] Sledge GW Jr,Neven P,Inoue K.MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy..J Clin Oncol2017;35:2875-84

[88] Carlson BA,Sausville EA,Worland PJ.Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells..Cancer Res1996;56:2973-8

[89] Losiewicz MD,Kaur G,Worland PJ.Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275..Biochem Biophys Res Commun1994;201:589-95

[90] Caracciolo V,Romano G,Cimini AM.Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development..Cell Cycle2012;11:1202-16

[91] Cobanoglu G,Ozkan A.Flavopiridol’s antiproliferative effects in glioblastoma multiforme..J Cancer Res Ther2016;12:811-7

[92] Alonso M,Miller DC.Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway..Mol Cancer Ther2003;2:139-50

[93] Newcomb EW,Entzminger Y,Schnee T.Flavopiridol inhibits the growth of GL261 gliomas in vivo: implications for malignant glioma therapy..Cell Cycle2004;3:230-4

[94] Meijer L,Mulner O,Blow JJ.Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5..Eur J Biochem1997;243:527-36

[95] Leitch AE,Marwick JA,Haslett C.Cyclin-dependent kinases 7 and 9 specifically regulate neutrophil transcription and their inhibition drives apoptosis to promote resolution of inflammation..Cell Death Differ2012;19:1950-61 PMCID:PMC3504709

[96] Kolodziej M,Di Fazio P,Ocker M.Roscovitine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study..Oncol Rep2015;34:1549-56

[97] Kim EH,Shin DY.Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP..Oncogene2004;23:446-56

[98] Murphy AC,Noonan J,Schimansky S.Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis..Apoptosis2014;19:629-42 PMCID:PMC3938842

[99] Pandey V,Narne P.Roscovitine effectively enhances antitumor activity of temozolomide in vitro and in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis..Sci Rep2019;9:5012 PMCID:PMC6428853

[100] Menn B,Blevins TL,Meijer L.Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models..PLoS One2010;5:e12117 PMCID:PMC2920814

[101] Brasca MG,Ballinari D,Casale E.Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor..J Med Chem2009;52:5152-63

[102] Albanese C,Amboldi N,Festuccia C.Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier..Br J Pharmacol2013;169:156-66 PMCID:PMC3632246

[103] Parry D,Shanahan F,Prabhavalkar D.Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor..Mol Cancer Ther2010;9:2344-53

[104] Nguyen TK.Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism..Mol Cancer Ther2014;13:662-74 PMCID:PMC3970263

[105] Chen Z,Pang JC,Bieerkehazhi S.Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity..Sci Rep2016;6:29090 PMCID:PMC4932496

[106] Jane EP,Cavaleri JM,Rajasekar T.Dinaciclib, a cyclin-dependent kinase inhibitor promotes proteasomal degradation of Mcl-1 and enhances ABT-737-mediated cell death in malignant human glioma cell lines..J Pharmacol Exp Ther2016;356:354-65 PMCID:PMC6047232

[107] Law ME,Narayan S.Cyclin-dependent kinase inhibitors as anticancer therapeutics..Mol Pharmacol2015;88:846-52 PMCID:PMC4613943

[108] Ali MA,Habib AA.SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor..Neoplasia2007;9:370-81 PMCID:PMC1877978

[109] Ali MA,Ding LH,Habib AA.SNS-032 prevents hypoxia-mediated glioblastoma cell invasion by inhibiting hypoxia inducible factor-1alpha expression..Int J Oncol2009;34:1051-60

[110] Chen R,Chubb S,Fox JA.Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia..Blood2009;113:4637-45 PMCID:PMC2680368

[111] Conroy A,Walker D,Hoch U.SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples..Cancer Chemother Pharmacol2009;64:723-32

[112] Erbayraktar Z,Erbayraktar RS.Cell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness..Cancer Cell Int2016;16:88 PMCID:PMC5116134

[113] Newcomb EW,Entzminger Y,Friedlander D.Flavopiridol induces mitochondrial-mediated apoptosis in murine glioma GL261 cells via release of cytochrome c and apoptosis inducing factor..Cell Cycle2003;2:243-50

[114] Michaud K,Oermann E,Zhong WZ.Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts..Cancer Res2010;70:3228-38 PMCID:PMC2855904

[115] Whittaker S,Joshi S,Johns T.Combination of palbociclib and radiotherapy for glioblastoma..Cell Death Discov2017;3:17033 PMCID:PMC5494656

[116] Sepulveda-Sanchez JM,Alonso M,Vicente E.Phase II trial of palbociclib in recurrent RB-positive anaplastic oligodendroglioma: a Spanish group for research in neurooncology (GEINO) trial..J Clin Oncol2019;37:2038

[117] Patel YT,Baker SJ,Stewart CF.CNS penetration of the CDK4/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors..Cancer Chemother Pharmacol2019;84:447-52

[118] Martinez-Chavez A,Rosing H,Tibben M.P-glycoprotein limits ribociclib brain exposure and CYP3A4 restricts its oral bioavailability..Mol Pharm2019;16:3842-52

[119] Tien AC,Derogatis A,Mehta S.ACTR-45. Phase 0/2 study of ribociclib in patients with recurrent glioblastoma..Neuro-Oncology2018;20:vi21 PMCID:PMC6216383

[120] Raub TJ,Kulanthaivel P,Ajamie RT.Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft..Drug Metab Dispos2015;43:1360-71

[121] Tolaney SM,Thornton D,Costigan TM.Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer..J Clin Oncol2017;35:1019

[122] Tsang J,Gosa L,Cloughesy T.EXTH-67. TG02, a brain-penetrant multi-CDK inhibitor, potently suppresses MYC-driven glioblastoma..Neuro Oncol2017;19:vi87-8 PMCID:PMC5692149

[123] Su YT,Wang H,Zhang Q.Novel targeting of transcription and metabolism in glioblastoma..Clin Cancer Res2018;24:1124-37

[124] Le Rhun E,Lohmann B,Schneider H.Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition..Int J Cancer2019;145:242-53

[125] Wu J,Cordova C,Penas-Prado M.Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults..J Clin Oncol2019;37:2031